Original post:
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
Related Post
- TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented... - April 30th, 2024
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma - April 30th, 2024
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease - April 30th, 2024
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - April 30th, 2024
- Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve - April 30th, 2024
- Oculis Publishes Invitation to the Annual General Meeting - April 30th, 2024
- OpGen Provides Update on Business Operations and Strategic Opportunities - April 30th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 - April 30th, 2024
- QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance - April 30th, 2024
- ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 - April 30th, 2024
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers... - April 30th, 2024
- Travere Therapeutics to Report First Quarter 2024 Financial Results - April 30th, 2024
- Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - April 30th, 2024
- Better Choice Company Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - April 30th, 2024
- BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results - April 30th, 2024
- Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 - April 30th, 2024
- BeyondSpring Files 2023 Annual Report on Form 20-F - April 30th, 2024
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - April 30th, 2024
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet... - April 30th, 2024
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 - April 30th, 2024
- Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
- Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
- Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
- Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
- Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of... - April 28th, 2024
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
- CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
- BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
- Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
- Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
- Financière de Tubize - Dividend approval - April 28th, 2024
- Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
- RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership - April 24th, 2024
- T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 - April 24th, 2024
- Eko2o S.A.S., a Majority-Controlled Subsidiary of MedCana/SFWJ Advances as Leading Infrastructure Supplier for Colombia’s Top Flower Producers - April 24th, 2024
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy - April 24th, 2024
- ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences - April 24th, 2024
- Spectral AI Names Erich Spangenberg CEO of its IP Focused Subsidiary and Explores Potential Spin-Off of that Subsidiary - April 24th, 2024
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting - April 24th, 2024
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- Immunocore announces upcoming presentation and posters at ASCO 2024 - April 24th, 2024
- Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual... - April 24th, 2024
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO - April 24th, 2024
- Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting - April 24th, 2024
- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination... - April 24th, 2024
- BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in... - April 24th, 2024
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- BrightInsight Recognized Among Newsweek’s World’s Best Digital Health Companies 2024 List - April 24th, 2024
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - April 24th, 2024
- Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF format) - April 24th, 2024
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of... - April 24th, 2024
- Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene... - April 23rd, 2024
- GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024 - April 23rd, 2024
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting - April 23rd, 2024
- Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual... - April 23rd, 2024
- Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at... - April 23rd, 2024
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - April 23rd, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting - April 23rd, 2024
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs - April 23rd, 2024
- Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024 - April 23rd, 2024
- Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy - April 23rd, 2024
- Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting - April 23rd, 2024
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy... - April 23rd, 2024
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting - April 23rd, 2024
- Scorpius Holdings Announces Receipt of Filing Delinquency Notification - April 23rd, 2024
- Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at... - April 23rd, 2024
- Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - April 23rd, 2024
- Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American... - April 23rd, 2024
- Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice - April 23rd, 2024
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) - April 23rd, 2024
- Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT)... - April 23rd, 2024
Recent Comments